Forest lab has sued Glenmark Pharma for Savella patent infringement. New York-based Forest has claimed that that Glenmark's abbreviated new drug application for the sale of milnacipran hydrochloride in 12.5, 25, 50 and 100 milligram dosage strengths would infringe on several patents it holds that indicate methods for treating fibromyalgia. Those patents are not due to expire until at least 2021.
Savella, or milnacipran hydrochloride, is a serotonin-norepinephrine reuptake inhibitor used to treat fibromyalgia, a disease characterized by chronic widespread pain throughout the body.
Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: